Cancer
Malignant Ovarian Neoplasm
CI-CAN-00003205Explore in graph →
Top-level685 active trials5 approved drugs83 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00003205Explore in graph →
Clinical trials
3,087 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (437)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00954174 | Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer | unknown | Phase 3 | 637 | GOG FoundationNETWORK | 2 | Sep 30, 2021 | clinicaltrials |
| NCT01170650 | Study for Women With Platinum Resistant Ovarian Cancer Evaluating EC145 in Combination With Doxil® (PROCEED)(PROCEED) | terminated | Phase 3 | 441 | EndocyteINDUSTRY | 0 | Sep 30, 2021 |
| clinicaltrials |
| NCT04679064 | Trial on NIraparib-TSR-042 (Dostarlimab) vs Physician's Choice CHEmotherapy in Recurrent, Ovarian, Fallopian Tube or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment(NItCHE-MITO33) | unknown | Phase 3 | 427 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Aug 27, 2021 | clinicaltrials |
| NCT03806049 | Trial Comparing Niraparib-bevacizumab-Dostarlimab and Niraparib-bevacizumab to Standard of Care in Recurrent Ovarian Cancer | withdrawn | Phase 3 | 0 | Nordic Society of Gynaecological Oncology - Clinical Trials UnitOTHER | 3 | Jul 15, 2021 | clinicaltrials |
| NCT00053352 | Surgery and Combination Chemotherapy in Treating Children With Extracranial Germ Cell Tumors | completed | Phase 3 | 302 | Children's Oncology GroupNETWORK | 6 | Jul 13, 2021 | clinicaltrials |
| NCT01837251 | Evaluation of Optimal Treatment With Bevacizumab in Patients With Platinum-sensitive Recurrent Ovarian Cancer | completed | Phase 3 | 682 | AGO Research GmbHINDUSTRY | 6 | Jul 13, 2021 | clinicaltrials |
| NCT03709316 | A Study of ZL-2306 (Niraparib) as Maintenance Treatment Following First-line Chemotherapy in Patients With Advanced Ovarian Cancer | unknown | Phase 3 | 384 | Zai Lab (Shanghai) Co., Ltd.INDUSTRY | 1 | Jun 2, 2021 | clinicaltrials |
| NCT04337632 | Evaluation of the Sensitivity to Different Chemotherapy Regimens in Platinum-Partial Sensitive Recurrent Ovarian Cancer | unknown | Phase 3 | 338 | Hunan Cancer HospitalOTHER | 1 | Apr 8, 2021 | clinicaltrials |
| NCT00866697 | Efficacy and Safety of Pazopanib Monotherapy After First Line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 3 | 940 | Novartis PharmaceuticalsINDUSTRY | 17 | Feb 16, 2021 | clinicaltrials |
| NCT00262990 | Patupilone Versus Doxorubicin in Patients With Ovarian, Primary Fallopian, or Peritoneal Cancer | completed | Phase 3 | 829 | Novartis PharmaceuticalsINDUSTRY | 12 | Dec 17, 2020 | clinicaltrials |
| NCT02490488 | Masitinib in Combination With Gemcitabine in Advanced/Metastatic Epithelial Ovarian Cancer Patients | completed | Phase 2 / Phase 3 | 248 | AB ScienceINDUSTRY | 6 | Dec 8, 2020 | clinicaltrials |
| NCT01461850 | Surgical Complications Related to Primary or Interval Debulking in Ovarian Neoplasm(SCORPION) | completed | Phase 3 | 171 | Catholic University of the Sacred HeartOTHER | 1 | Oct 14, 2020 | clinicaltrials |
| NCT02631876 | A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer(FORWARD I) | completed | Phase 3 | 366 | ImmunoGen, Inc.INDUSTRY | 13 | Oct 14, 2020 | clinicaltrials |
| NCT04237090 | Feasibility of a Clinical Trial Comparing the Use of Cetirizine to Replace Diphenhydramine in the Prevention of Reactions Related to Paclitaxel(PREMED-F1) | completed | Phase 3 | 27 | Ciusss de L'Est de l'Île de MontréalOTHER | 1 | Oct 12, 2020 | clinicaltrials |
| NCT04473339 | A Randomized Prospective Trail of HIPEC in Recurrent Ovarian Cancer Patients With HRR Mutation | unknown | Phase 3 | 280 | CAI HongbingOTHER | 1 | Sep 9, 2020 | clinicaltrials |
| NCT04515602 | Stratified Evaluation of PDS and NACT-IDS in Ovarian Cancer (FOCUS) | not yet recruiting | Phase 3 | 410 | Shanghai Gynecologic Oncology GroupOTHER_GOV | 1 | Aug 27, 2020 | clinicaltrials |
| NCT02718417 | Avelumab in Previously Untreated Patients With Epithelial Ovarian Cancer (JAVELIN OVARIAN 100) | terminated | Phase 3 | 998 | PfizerINDUSTRY | 25 | Jul 14, 2020 | clinicaltrials |
| NCT03371693 | Cytoreductive Surgery(CRS) Plus Hyperthermic Intraperitoneal Chemotherapy(HIPEC) With Lobaplatin in Advanced and Recurrent Epithelial Ovarian Cancer(HIPECOV) | unknown | Phase 3 | 112 | Zhongnan HospitalOTHER | 1 | May 29, 2020 | clinicaltrials |
| NCT02421588 | Clinical Trial of Lurbinectedin (PM01183) in Platinum Resistant Ovarian Cancer Patients(CORAIL) | completed | Phase 3 | 442 | PharmaMarINDUSTRY | 1 | Apr 3, 2020 | clinicaltrials |
| NCT00028743 | Combination Chemotherapy Regimens in Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer | completed | Phase 3 | 819 | NCIC Clinical Trials GroupNETWORK | 1 | Apr 2, 2020 | clinicaltrials |
| NCT00477282 | Karenitecin Versus Topotecan in Patients With Advanced Epithelial Ovarian Cancer | completed | Phase 3 | 509 | BioNumerik Pharmaceuticals, Inc.INDUSTRY | 5 | Mar 12, 2020 | clinicaltrials |
| NCT00693342 | Vaccine Therapy and OPT-821 or OPT-821 Alone in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer in Complete Remission | withdrawn | Phase 3 | 0 | Gynecologic Oncology GroupNETWORK | 0 | Feb 24, 2020 | clinicaltrials |
| NCT00226915 | Trial of Tri-weekly TJ Versus Weekly TJ for Stage II-IV Mullerian Carcinoma | completed | Phase 3 | 637 | Japanese Gynecologic Oncology GroupOTHER | 1 | Feb 17, 2020 | clinicaltrials |
| NCT01091636 | Intraoperative Hyperthermic Intraperitoneal Chemotherapy With Ovarian Cancer | completed | Phase 2 / Phase 3 | 184 | National Cancer Center, KoreaOTHER_GOV | 1 | Feb 17, 2020 | clinicaltrials |
| NCT00001806 | Methods in Education for Breast Cancer Genetics | completed | Phase 3 | 170 | National Cancer Institute (NCI)NIH | 1 | Dec 12, 2019 | clinicaltrials |
| NCT03693248 | Reduction Of Cycles of neOadjuvant Chemotherapy for Advanced Epithelial Ovarian, Fallopian and Primary Peritoneal Cancer(ROCOCO) | unknown | Phase 3 | 298 | Seoul National University HospitalOTHER | 1 | Dec 10, 2019 | clinicaltrials |
| NCT03373058 | Efficacy of HIPEC in the Treatment of Advanced-Stage Epithelial Ovarian Cancer After Cytoreductive Surgery(EHTASEOCCS) | unknown | Phase 3 | 310 | Affiliated Cancer Hospital & Institute of Guangzhou Medical UniversityOTHER | 1 | Nov 6, 2019 | clinicaltrials |
| NCT03220932 | Cytoreductive Surgery and HIPEC in First or Secondary Platinum-resistant Recurrent Ovarian Epithelial Cancer(HIPOVA-01) | unknown | Phase 3 | 132 | Hospices Civils de LyonOTHER | 1 | Nov 1, 2019 | clinicaltrials |
| NCT04000295 | Apatinib and Etoposide Capsule Versus Weekly Paclitaxel in Patients With Platinum Resistant Ovarian Cancer | unknown | Phase 3 | 280 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Oct 8, 2019 | clinicaltrials |
| NCT04101760 | Granulocyte Colony Stimulating Factor for for the Prevention of Febrile Neutropenia in Epithelial Ovarian Cancer | unknown | Phase 3 | 200 | Lei LiOTHER | 1 | Oct 8, 2019 | clinicaltrials |
| NCT04063527 | Phase III Trial of Stage I Ovarian Cancer After Surgery | recruiting | Phase 3 | 360 | Japanese Gynecologic Oncology GroupOTHER | 2 | Aug 30, 2019 | clinicaltrials |
| NCT04055038 | Efficacy of Platinum-based Chemotherapy in Platinum-resistant Ovarian Cancer) (EPITOC)(EPITOC) | unknown | Phase 2 / Phase 3 | 164 | Blokhin's Russian Cancer Research CenterOTHER | 1 | Aug 13, 2019 | clinicaltrials |
| NCT00041080 | Tamoxifen Compared With Thalidomide in Treating Women With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | completed | Phase 3 | 139 | National Cancer Institute (NCI)NIH | 1 | Jul 30, 2019 | clinicaltrials |
| NCT00262847 | Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer | completed | Phase 3 | 1,873 | National Cancer Institute (NCI)NIH | 4 | Jul 23, 2019 | clinicaltrials |
| NCT00003644 | Carboplatin Plus Paclitaxel With or Without Continued Low-Dose Paclitaxel in Treating Patients With Early-Stage Ovarian Cancer | completed | Phase 3 | 571 | Gynecologic Oncology GroupNETWORK | 2 | Jun 4, 2019 | clinicaltrials |
| NCT01218490 | Pelvic and Aortic-cava Lymphadenectomy Randomized for Ovarian Cancer(CARACO) | suspended | Phase 3 | 450 | Institut Cancerologie de l'OuestOTHER | 1 | May 16, 2019 | clinicaltrials |
| NCT00003214 | Chemosensitivity Testing to Assign Treatment for Patients With Stage III or Stage IV Ovarian Cancer | completed | Phase 3 | 300 | Swiss Cancer InstituteOTHER | 1 | May 15, 2019 | clinicaltrials |
| NCT00011986 | Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer | completed | Phase 3 | 4,312 | Gynecologic Oncology GroupNETWORK | 1 | Apr 16, 2019 | clinicaltrials |
| NCT03740464 | Long-acting G-CSF for Febrile Neutropenia | unknown | Phase 3 | 556 | Lei LiOTHER | 1 | Nov 14, 2018 | clinicaltrials |
| NCT00426257 | Secondary Debulking Surgery +/- Hyperthermic Intraperitoneal Chemotherapy in Stage III Ovarian Cancer | completed | Phase 3 | 242 | The Netherlands Cancer InstituteOTHER | 1 | Aug 24, 2018 | clinicaltrials |
| NCT02681432 | Hyperthermic Intraperitoneal Chemotherapy With Paclitaxel in Advanced Ovarian Cancer(hipecova) | unknown | Phase 3 | 60 | PEDRO VILLAREJO CAMPOSOTHER | 1 | Aug 21, 2018 | clinicaltrials |
| NCT02107066 | Women's Activity and Lifestyle Study in Connecticut(WALC) | completed | Phase 3 | 144 | Yale UniversityOTHER | 1 | Apr 20, 2018 | clinicaltrials |
| NCT00719303 | Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | unknown | Phase 3 | 1,070 | Gynecologic Oncology GroupNETWORK | 1 | Feb 19, 2018 | clinicaltrials |
| NCT03180177 | Efficacy of HIPEC as NACT and Postoperative Chemotherapy in the Treatment of Advanced-Stage Epithelial Ovarian Cancer(EHNPCTASEOC) | unknown | Phase 3 | 263 | Shu-Zhong CuiOTHER | 1 | Jan 24, 2018 | clinicaltrials |
| NCT01281254 | AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2) | terminated | Phase 3 | 223 | AmgenINDUSTRY | 18 | Dec 2, 2017 | clinicaltrials |
| NCT00434642 | A Study of Carboplatin and Gemcitabine Plus Bevacizumab in Patients With Ovary, Peritoneal, or Fallopian Tube Carcinoma(OCEANS) | completed | Phase 3 | 484 | Genentech, Inc.INDUSTRY | 0 | Aug 9, 2017 | clinicaltrials |
| NCT01684878 | Pertuzumab in Platinum-Resistant Low Human Epidermal Growth Factor Receptor 3 (HER3) Messenger Ribonucleic Acid (mRNA) Epithelial Ovarian Cancer (PENELOPE) | completed | Phase 3 | 208 | Hoffmann-La RocheINDUSTRY | 10 | May 23, 2017 | clinicaltrials |
| NCT00324324 | Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant | terminated | Phase 3 | 240 | OHSU Knight Cancer InstituteOTHER | 1 | May 9, 2017 | clinicaltrials |
| NCT01493505 | TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer | terminated | Phase 3 | 1,015 | AmgenINDUSTRY | 14 | Feb 23, 2017 | clinicaltrials |
| NCT02311907 | Glutathione in Preventing Peripheral Neuropathy Caused by Paclitaxel and Carboplatin in Patients With Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer | completed | Phase 3 | 195 | Alliance for Clinical Trials in OncologyOTHER | 1 | Feb 23, 2017 | clinicaltrials |
Data updated 23 days agoSource updated Sep 30, 2021source: clinicaltrials